Beta Bionics Inc (NASDAQ: BBNX)’s stock price has gone decline by -2.47 in comparison to its previous close of 18.23, however, the company has experienced a -6.96% decrease in its stock price over the last five trading days. seekingalpha.com reported 2025-05-10 that Beta Bionics, Inc. (NASDAQ:BBNX ) Q1 2025 Results Conference Call May 6, 2025 4:30 PM ET Company Participants Blake Beber – Head, IR Sean Saint – President and Chief Executive Officer Stephen Feider – Chief Financial Officer Conference Call Participants Matthew O’Brien – Piper Sandler Mike Kratky – Leerink Partners Matthew Blackman – Stifel Travis Steed – Bank of America Jeffrey Cohen – Ladenburg Thalmann Brooks O’Neil – Lake Street Capital Markets Kelly Close – Close Concerns Operator Good afternoon, and welcome to the Beta Bionics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Is It Worth Investing in Beta Bionics Inc (NASDAQ: BBNX) Right Now?
Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for BBNX is 33.23M, and at present, short sellers hold a 12.44% of that float. On June 19, 2025, the average trading volume of BBNX was 557.53K shares.
BBNX’s Market Performance
BBNX’s stock has seen a -6.96% decrease for the week, with a 17.75% rise in the past month and a 12.60% gain in the past quarter. The volatility ratio for the week is 3.41%, and the volatility levels for the past 30 days are at 4.93% for Beta Bionics Inc The simple moving average for the past 20 days is 0.44% for BBNX’s stock, with a 11.13% simple moving average for the past 200 days.
Analysts’ Opinion of BBNX
Many brokerage firms have already submitted their reports for BBNX stocks, with Truist repeating the rating for BBNX by listing it as a “Buy.” The predicted price for BBNX in the upcoming period, according to Truist is $26 based on the research report published on June 16, 2025 of the current year 2025.
Lake Street, on the other hand, stated in their research note that they expect to see BBNX reach a price target of $30. The rating they have provided for BBNX stocks is “Buy” according to the report published on June 12th, 2025.
Wolfe Research gave a rating of “Outperform” to BBNX, setting the target price at $20 in the report published on May 30th of the current year.
BBNX Trading at 24.43% from the 50-Day Moving Average
After a stumble in the market that brought BBNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.43% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBNX starting from Sean Saint, who proposed sale 3,439 shares at the price of $17.89 back on Jun 02 ’25. After this action, Sean Saint now owns shares of Beta Bionics Inc, valued at $61,524 using the latest closing price.
Hopman Mark, the Chief Commercial Officer of Beta Bionics Inc, sale 868 shares at $17.89 during a trade that took place back on Jun 02 ’25, which means that Hopman Mark is holding 34,132 shares at $15,529 based on the most recent closing price.
Stock Fundamentals for BBNX
Current profitability levels for the company are sitting at:
- -0.77 for the present operating margin
- 0.54 for the gross margin
The net margin for Beta Bionics Inc stands at -1.02. The total capital return value is set at -0.16.
Based on Beta Bionics Inc (BBNX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -6.65.
Currently, EBITDA for the company is -44.1 million with net debt to EBITDA at 0.7. When we switch over and look at the enterprise to sales, we see a ratio of 10.86. The receivables turnover for the company is 6.15for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.88.
Conclusion
To sum up, Beta Bionics Inc (BBNX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
